Showing 691-700 of 2293 results for "".
- Interim Data Suggest Clinical Improvement Occurring With Nanocrystalline Gold Treatment of Multiple Sclerosishttps://practicalneurology.com/news/interim-data-suggest-clinical-improvement-occurring-with-nanocrystalline-gold-treatment-of-multiple-sclerosis/2469837/Updated interim data from 2 Phase 2 clinical trials support CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for multiple sclerosis (MS). Data from the Phase 2 VISIONARY-MS study (NCT03536559) suggest treatment with nanocrystal
- Relapses in Multiple Sclerosis Significantly Increased Likelihood of Disability Worseninghttps://practicalneurology.com/news/relapses-in-multiple-sclerosis-significantly-increased-likelihood-of-disability-worsening/2469833/A new study published in Brain has revealed detailed information on how individuals with multiple sclerosis (MS) acquire disability. In retrospective analysis of observational and randomized controlled clinical trials that included over 27,000 individuals with MS, progression inde
- Different Antibody Response to COVID-19 Vaccine With Different Disease-Modifying Therapies for Multiple Sclerosishttps://practicalneurology.com/news/different-antibody-response-to-covid-19-vaccine-with-different-disease-modifying-therapies-for-multiple-sclerosis/2469722/A new analysis of data from the MS PATHS network showed immune response to the COVID-19 vaccine among people with multiple sclerosis (MS) varied with disease-modifying type. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (
- New Multiple Sclerosis Registry Launcheshttps://practicalneurology.com/news/new-multiple-sclerosis-registry-launches/2469648/A technology company with a focus on chronic diseases (OMI; Boston, MA) has launched a multiple sclerosis (MS) registry. The OMI MS registry is a continually updating database of more than 20,000 patients prospectively followed with deep clinical, laboratory, and other data such
- Ublituximab Treatment Lessened Disability for People With Multiple Sclerosishttps://practicalneurology.com/news/ublituximab-treatment-lessened-disability-for-people-with-multiple-sclerosis/2469565/Treatment of people with relapsing multiple sclerosis (MS) with ublituximab (UTX)(TG Therapeutics; New York, NY) slowed progression of MS as measured with biomarkers and disability progression. Compared with teriflunomide (TFM), ublituximab reduced annualized rate of relapse (ARR), gadolinium enh
- Prescription Patterns in Multiple Sclerosis Changinghttps://practicalneurology.com/news/prescription-patterns-in-multiple-sclerosis-changing/2469504/Neurologists are prescribing more oral disease-modifying therapy (DMT) for initial treatment of multiple sclerosis (MS) than ever. Out of 1,018 individuals with multiple sclerosis (MS) in a 3-month period, close to half received an oral DMT as their first treatment. Only 4 years ago, the proporti
- Multiple Sclerosis Does Not Increase Risk of Contracting COVID-19, But Some Treatments, EDSS, and Progressive Status May Increase COVID-19 Severityhttps://practicalneurology.com/news/multiple-sclerosis-does-not-increase-risk-of-contracting-covid-19-but-some-treatments-edss-and-progressive-status-may-increase-covid-19-severity/2469386/In an encore session of MS Virtual 2020, the joint American and European Committees on Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS) online meeting, new data regarding SARS-COV2 infection rates in people with MS were reported. Effects of disease-modifying treatments for multiple
- New Resource Center for People Living with Multiple Sclerosishttps://practicalneurology.com/news/new-resource-center-for-people-living-with-multiple-sclerosis/2469307/The Treatment and Adherence Resource Center within MyMSTeam, a social network for individuals living with multiple sclerosis (MS) has officially launched. The Resource Center is designed to help individuals with MS and their families understand the importance of starting treatment and provides ac
- Ozanimod, a New Oral Treatment for Relapsing Multiple Sclerosis, Now Availablehttps://practicalneurology.com/news/ozanimod-a-new-oral-treatment-for-relapsing-multiple-sclerosis-now-available/2469283/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, Princeton, NJ) for treatment of relapsing forms of multiple sclerosis (MS) on March 25, 2020. Ozanimod, 0.92 mg, is a new once-daily oral medication for adults with relapsing MS. Ozanimod
- Ocrelizumab Direct-to-Consumer Advertising—What Clinicians Need to Knowhttps://practicalneurology.com/news/ocrelizumab-direct-to-consumer-advertisingwhat-clinicians-need-to-know/2469121/A new direct-to-consumer (DTC) campaign has been launched for the MS treatment ocrelizumab (Ocrevus; Genentech, South San Francisco, CA). Although the advertisements may resonate with all generations of people living with MS, this campaign specifically targets the millennial generation (those who